Regeneron Pharmaceuticals stock (US7739031091): Q1 earnings beat with $9.47 EPS

Regeneron Pharmaceuticals reported Q1 2026 earnings on April 29, beating estimates with $9.47 EPS and $3.61B revenue, up 19% YoY. Stock traded at $719.88 on May 14.

Regeneron Pharmaceuticals released Q1 2026 earnings on April 29, 2026, reporting earnings per share of $9.47, surpassing analyst consensus of $8.91 by $0.56. Quarterly revenue increased 19.0% year-over-year to $3.61 billion, exceeding estimates of $3.48 billion, according to MarketBeat as of May 14, 2026.

REGN stock opened at $719.88 on Thursday, May 14, 2026, with a 50-day moving average of $747.55 and 200-day average of $744.35, per MarketBeat as of May 14, 2026. The closing price stood at $719.88 on May 13, 2026.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Regeneron Pharmaceuticals, Inc.
• Sector/industry: Biotechnology
• Headquarters/country: United States
• Core markets: US, Europe
• Key revenue drivers: Eylea, Dupixent
• Home exchange/listing venue: Nasdaq (REGN)
• Trading currency: USD

Regeneron Pharmaceuticals: core business model

Regeneron Pharmaceuticals develops biologic medicines for serious diseases through genetic insights and advanced technologies like VelociSuite. The company focuses on monoclonal antibodies and gene therapies, with key products addressing eye diseases, allergies, and cancer. Its collaboration with Sanofi on Dupixent has been a major growth driver.

Regeneron operates from Tarrytown, New York, with a pipeline spanning oncology, neuroscience, and rare diseases. The business model emphasizes R&D investment, supported by revenue from approved drugs like Eylea and Libtayo.

Main revenue and product drivers for Regeneron Pharmaceuticals

Eylea, an anti-VEGF treatment for retinal diseases, remains a top revenue generator. Dupixent, co-developed with Sanofi, targets atopic dermatitis and asthma, contributing significantly to sales growth. Q1 2026 revenue of $3.61 billion reflects strength in these franchises, per the April 29 report.

Trailing twelve-month EPS reached $41.04 with net income of $4.50 billion, as reported by MarketBeat. Future EPS is projected to grow 11.89% to $41.51 per share next year.

Industry trends and competitive position

The biotech sector faces patent cliffs and biosimilar competition, but Regeneron's diversified pipeline and partnerships position it strongly. Eylea faces biosimilar pressure, yet oncology expansions like Libtayo bolster resilience. Regeneron's genetic research platform differentiates it in precision medicine.

Why Regeneron Pharmaceuticals matters for US investors

Listed on Nasdaq, Regeneron derives substantial revenue from the US market, where Medicare coverage supports drugs like Eylea. Its exposure to US healthcare spending and innovation hubs makes it relevant for investors tracking biotech growth amid rising demand for biologics.

Conclusion

Regeneron Pharmaceuticals delivered a strong Q1 2026 earnings beat, with revenue and EPS exceeding expectations amid robust product demand. The company's pipeline and US market exposure continue to drive performance, though competition remains a factor. Investors monitor upcoming catalysts like further trial data.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.